Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care

AUTOR(ES)

Da Silva, Philip R

FONTE

The Royal Society of Medicine

RESUMO

In the UK, the National Institute for Clinical Excellence has recommended the use of neuraminidase inhibitors for elderly and at-risk patients who present with influenza-like illness within 36 hours of symptom onset. However, few data exist to enable primary care trusts to evaluate the logistics and costs of prescribing. We sought to determine, during a confirmed influenza outbreak, the proportion of eligible patients who currently present in time to benefit from treatment with a neuraminidase inhibitor, and to develop the findings into a model for evaluating potential prescribing costs. Within a single primary care group, demographic and co-morbidity data were collected on all patients consulting their general practitioner or attending an out-of-hours centre with influenza-like illness during the outbreak period.

Documentos Relacionados

• Treatment of influenza with neuraminidase inhibitors: virological implications.
• The role of neuraminidase inhibitors in the treatment and prevention of influenza
• Prescription of neuraminidase inhibitors for influenza
• Potential phytotoxicity associated with the use of soil urease inhibitors
• Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children